ACADIA Pharmaceuticals (ACAD) Competitors $16.87 +0.14 (+0.84%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACAD vs. CTLT, PCVX, QGEN, ITCI, ROIV, ASND, RVMD, LNTH, LEGN, and NUVLShould you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Catalent (CTLT), Vaxcyte (PCVX), Qiagen (QGEN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. ACADIA Pharmaceuticals vs. Catalent Vaxcyte Qiagen Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Legend Biotech Nuvalent Catalent (NYSE:CTLT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking. Does the MarketBeat Community prefer CTLT or ACAD? ACADIA Pharmaceuticals received 253 more outperform votes than Catalent when rated by MarketBeat users. Likewise, 73.20% of users gave ACADIA Pharmaceuticals an outperform vote while only 57.71% of users gave Catalent an outperform vote. CompanyUnderperformOutperformCatalentOutperform Votes64057.71% Underperform Votes46942.29% ACADIA PharmaceuticalsOutperform Votes89373.20% Underperform Votes32726.80% Does the media prefer CTLT or ACAD? In the previous week, Catalent had 6 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for Catalent and 5 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.75 beat Catalent's score of 0.42 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalent 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, CTLT or ACAD? Catalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Do analysts prefer CTLT or ACAD? Catalent presently has a consensus target price of $63.40, indicating a potential downside of 0.13%. ACADIA Pharmaceuticals has a consensus target price of $25.60, indicating a potential upside of 51.75%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Catalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalent 0 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.63 Is CTLT or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Catalent's net margin of -9.28%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Catalent's return on equity.Company Net Margins Return on Equity Return on Assets Catalent-9.28% -0.66% -0.24% ACADIA Pharmaceuticals 13.83%25.83%14.71% Which has stronger valuation & earnings, CTLT or ACAD? ACADIA Pharmaceuticals has lower revenue, but higher earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalent$4.42B2.61-$1.04B-$2.26-28.09ACADIA Pharmaceuticals$929.24M3.02-$61.29M$0.7821.63 Do insiders & institutionals have more ownership in CTLT or ACAD? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 0.3% of Catalent shares are held by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryACADIA Pharmaceuticals beats Catalent on 15 of the 18 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition Export to ExcelMetricACADIA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.81B$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio21.6310.4289.5817.17Price / Sales3.02195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book6.415.094.774.78Net Income-$61.29M$151.83M$120.15M$225.60M7 Day Performance-2.26%-2.13%-1.92%-1.23%1 Month Performance4.26%-3.10%11.47%3.36%1 Year Performance-42.85%11.54%30.54%16.60% ACADIA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals3.8468 of 5 stars$16.87+0.8%$25.60+51.7%-41.9%$2.81B$929.24M21.63510High Trading VolumeCTLTCatalent2.7663 of 5 stars$63.47+0.6%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.6009 of 5 stars$90.74+3.4%$147.50+62.6%+45.4%$11.31BN/A-19.07160Analyst ForecastInsider TradeQGENQiagen3.512 of 5 stars$45.42+0.0%$51.15+12.6%+3.1%$10.36B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0477 of 5 stars$84.52+1.8%$97.23+15.0%+27.8%$8.96B$612.78M-95.91560ROIVRoivant Sciences3.0007 of 5 stars$12.14+2.5%$17.93+47.7%+16.2%$8.84B$129.13M2.10860Insider TradeASNDAscendis Pharma A/S3.1363 of 5 stars$135.74+4.5%$191.77+41.3%+12.6%$8.23B$327.43M-16.52640RVMDRevolution Medicines4.5486 of 5 stars$44.89-0.3%$63.67+41.8%+71.5%$7.55B$11.58M-12.54443Insider TradeLNTHLantheus4.3807 of 5 stars$94.27+1.3%$130.00+37.9%+53.4%$6.55B$1.50B15.42834Analyst ForecastLEGNLegend Biotech1.5523 of 5 stars$33.83-3.7%$81.54+141.0%-43.2%$6.18B$520.18M-36.971,800NUVLNuvalent2.1944 of 5 stars$86.65-0.2%$112.60+29.9%+16.9%$6.16BN/A-25.0340Insider TradeNews CoveragePositive News Related Companies and Tools Related Companies Catalent Alternatives Vaxcyte Alternatives Qiagen Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Lantheus Alternatives Legend Biotech Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACAD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
